- Home
- SGU vs CVRX Comparison
SGU vs CVRX Comparison
Compare SGU & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- CVRX
- Stock Information
- Founded
- SGU 1995
- CVRX 2000
- Country
- SGU United States
- CVRX United States
- Employees
- SGU N/A
- CVRX N/A
- Industry
- SGU Other Specialty Stores
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SGU Consumer Discretionary
- CVRX Health Care
- Exchange
- SGU Nasdaq
- CVRX Nasdaq
- Market Cap
- SGU 445.9M
- CVRX 419.8M
- IPO Year
- SGU 1995
- CVRX 2021
- Fundamental
- Price
- SGU $12.20
- CVRX $4.77
- Analyst Decision
- SGU
- CVRX Buy
- Analyst Count
- SGU 0
- CVRX 7
- Target Price
- SGU N/A
- CVRX $14.50
- AVG Volume (30 Days)
- SGU 28.5K
- CVRX 370.8K
- Earning Date
- SGU 05-07-2025
- CVRX 05-08-2025
- Dividend Yield
- SGU 6.07%
- CVRX N/A
- EPS Growth
- SGU 91.90
- CVRX N/A
- EPS
- SGU 1.69
- CVRX N/A
- Revenue
- SGU $1,803,079,000.00
- CVRX $52,870,000.00
- Revenue This Year
- SGU N/A
- CVRX $22.17
- Revenue Next Year
- SGU N/A
- CVRX $24.02
- P/E Ratio
- SGU $7.48
- CVRX N/A
- Revenue Growth
- SGU 2.38
- CVRX 25.62
- 52 Week Low
- SGU $9.64
- CVRX $5.81
- 52 Week High
- SGU $13.75
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- SGU 39.62
- CVRX 28.07
- Support Level
- SGU $12.03
- CVRX $7.30
- Resistance Level
- SGU $12.73
- CVRX $7.91
- Average True Range (ATR)
- SGU 0.44
- CVRX 0.56
- MACD
- SGU 0.01
- CVRX 0.12
- Stochastic Oscillator
- SGU 17.70
- CVRX 4.36
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.